Hundertmark Sarah

Liegl Constance, Bourauel Leonie, Aretz Benjamin, Walz Wolfgang, Hundertmark Sarah, Petrak Michael et al.

PAUL Glaucoma Implant offers sustained IOP reduction in refractory glaucoma, but often requires intraluminal stent removal for optimal control. Clinicians should anticipate potential complications like hypotony and tube exposure.

Liegl Constance, Hundertmark Sarah, Holz Frank G, Mercieca Karl

The EyeWatch system effectively lowered IOP in refractory glaucoma over three years, reducing medication needs. Most adjustments were early, but MRI caused transient IOP spikes.

Weber Constance, Samarghitan Diana, Bourauel Leonie, Walz Wolfgang, Hundertmark Sarah, Petrak Michael et al.

Removing the PAUL implant's intraluminal stent significantly lowers IOP but carries hypotony/hemorrhage risks, with most patients eventually needing additional drops. This highlights a trade-off between efficacy and complication risk.

Weber Constance, Hundertmark Sarah, Stasik Isabel, Holz Frank G, Mercieca Karl

This study found the PAUL Glaucoma Implant effectively lowered eye pressure and medication needs over two years in white patients, with a temporary stent preventing early hypotony and allowing further pressure reduction.

Weber Constance, Hundertmark Sarah, Liegl Raffael, Jauch Anna S, Stasik Isabel, Holz Frank G et al.

This study found the PAUL glaucoma implant effectively lowered eye pressure and medication use over one year, with a unique stent preventing early hypotony and allowing further pressure reduction.

Weber Constance, Ludwig Elisabeth, Hundertmark Sarah, Brinkmann Christian Karl, Petrak Michael, Holz Frank G et al.

Inferior trabectome surgery is safe and somewhat effective for glaucoma, but most patients still require eye drops and many need further surgery for adequate pressure control.